Abstract
Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy in the mid eighties of the past century clinically significant response rates as well as prolonged survival has been documented. This review summarizes seven Phase-III trials of systemic chemotherapy for advanced urothelial carcinoma as well as results from adjuvant and neoadjuvant Phase-III trials for muscle-invasive bladder cancer including the most recent reports.
| Translated title of the contribution | Systemic chemotherapy for transitional cell carcinoma of the urothelium |
|---|---|
| Original language | German |
| Pages (from-to) | 18-25 |
| Number of pages | 8 |
| Journal | Onkologie |
| Volume | 26 |
| Issue number | SUPPL. 4 |
| DOIs | |
| State | Published - 2003 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Systemic chemotherapy for transitional cell carcinoma of the urothelium'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver